Abera Bioscience (ABERA) investor relations material

Executive summary

• Achieved strong growth and stable profitability in Q1 2026, with 7% organic revenue growth adjusted for calendar effects and a stable adjusted EBITA margin of 12.9% (12.7% in Q1 2025).

• Net revenue reached NOK 3,005m (up from NOK 2,637m year-over-year), driven by increased headcount, higher billing rates, and improved billing ratio.

• Profit after tax was NOK 194m (NOK 257m in Q1 2025), with ordinary EPS at NOK 0.62 (NOK 0.85 in Q1 2025).

• High organizational activity with parallel progress in pneumococcal vaccine clinical preparations and accelerated preclinical influenza work, strengthening both short-term milestones and long-term potential in next-generation vaccines.

• Order book stood at NOK 7.6bn, slightly down from NOK 7.7bn in Q4 2025.

Financial highlights

• Adjusted EBITA was NOK 331m (NOK 335m in Q1 2025), with margin improvement after calendar adjustment.

• Net finance was NOK -40m (NOK 3m in Q1 2025), impacted by unrealized currency losses.

• Cash flow from operating activities was NOK 189m, in line with seasonal variations.

• Net sales for Q1 2026 were 0 KSEK, with other operating income of 3,553 KSEK, mainly from grants.

• Cash and cash equivalents at quarter-end were NOK 1,415m (NOK 1,552m at Q4 2025) and 26,041 KSEK (5,501 KSEK YoY), supported by the recent share issue.

Outlook and guidance

• Market expected to remain stable, but with uncertainty due to international political situation.

• Clinical trial application for the pneumococcal vaccine is imminent, with first-in-human studies planned for 2026.

• Private Buildings & Architecture market remains slow; infrastructure demand stable, supported by public spending.

• High activity expected in energy sector; mixed outlook for other industry segments due to geopolitical factors.

• Ongoing support from CEPI and UK Vaccine Network ensures funding for pandemic preparedness and vaccine platform development through at least mid-2026.